Equine Viral Arteritis (EVA)

Equine Viral Arteritis is a contagious viral disease of horses caused by equine arteritis virus, a member of the family Arteriviridae. This disease primarily affects the vascular system, causing inflammation of small blood vessels throughout the body, which leads to a wide range of clinical signs including fever, respiratory symptoms, limb edema, and conjunctivitis. One of the most significant aspects of EVA is its impact on reproduction, as infection can cause abortion in pregnant mares and establish persistent infection in stallions that become long-term carriers capable of transmitting the virus through breeding.

EVA occurs worldwide but with variable prevalence among different horse populations and breeds. Seroprevalence studies have shown that exposure rates vary dramatically, from less than five percent in some populations to over 80 percent in certain breeding populations, particularly Standardbreds in which the virus has become endemic. The disease gained significant attention when outbreaks caused substantial economic losses in the Thoroughbred industry during the 1980s, leading to the development of control programs and vaccination strategies. International regulations regarding EVA testing for breeding stallions reflect the disease's importance to the global horse industry.

The impact of EVA extends beyond individual animal health to affect breeding operations and international horse trade. Abortion storms can devastate breeding seasons, with losses of multiple pregnancies in affected herds. The establishment of carrier stallions creates ongoing transmission risk and may affect the marketability and use of valuable breeding animals. Regulations requiring EVA testing for international movement and breeding can complicate management of affected stallions. Additionally, clinical illness can temporarily affect performance horses, though most recover fully from acute infection.

Fortunately, EVA is manageable through a combination of testing, vaccination, and management practices. Most horses recover from acute infection without lasting effects, and the disease is rarely fatal except in young foals or debilitated animals. Vaccines are available that can prevent clinical disease and, when used strategically, protect mares from abortion and prevent establishment of the carrier state in stallions. However, the ability of vaccinated horses to seroconvert complicates the interpretation of surveillance testing, requiring careful record-keeping and strategic vaccination timing in breeding populations.

The primary cause of Equine Viral Arteritis is infection with equine arteritis virus, an RNA virus in the family Arteriviridae and order Nidovirales. The virus is relatively fragile in the environment compared to some other equine pathogens, but it can survive for extended periods in semen, particularly when cooled or frozen for artificial insemination. Only one serotype of equine arteritis virus is recognized, though molecular studies have identified genetic variation among strains that may influence virulence. The virus replicates in endothelial cells lining blood vessels and in macrophages, leading to the characteristic vascular inflammation.

No specific genetic or breed predisposition to EVA infection exists, as all horses are susceptible to the virus when exposed. However, certain breeds have higher seroprevalence due to historical patterns of virus circulation within those populations. Standardbreds have notably high seroprevalence rates in many countries, while Thoroughbreds have historically had lower exposure rates until outbreaks occur. The difference relates to virus introduction and spread within closed breeding populations rather than inherent susceptibility differences. Individual immune status, previous exposure, and vaccination history influence whether exposure results in clinical disease.

Environmental and management factors strongly influence EVA transmission dynamics. The virus spreads through two primary routes: respiratory transmission through aerosolized secretions and venereal transmission through infected semen. Respiratory spread occurs when susceptible horses are in close contact with acutely infected animals shedding virus in nasal secretions. Breeding or artificial insemination with semen from carrier stallions transmits the virus efficiently to mares and may result in widespread infection at breeding facilities. Aborted fetuses, placental membranes, and fetal fluids contain high virus concentrations and serve as sources of exposure.

Risk factors for EVA include exposure to carrier stallions through natural breeding or artificial insemination, attendance at events where horses from diverse populations commingle, and introduction of horses from populations with high seroprevalence. Young horses experiencing their first exposure typically develop clinical disease, while previously exposed horses may be protected. Pregnant mares are at particular risk for abortion following exposure. Stress, concurrent illness, and immunosuppression may increase disease severity. Breeding facilities that use multiple outside stallions or receive mares from various sources face increased introduction risk.

The pathophysiology of EVA centers on virus-induced damage to vascular endothelium, the cells lining blood vessels throughout the body. This endothelial damage leads to increased vascular permeability, allowing fluid to leak from blood vessels into surrounding tissues, causing the characteristic edema of the limbs, ventral abdomen, and around the eyes. Inflammation of small arteries may cause tissue necrosis in some organs. In pregnant mares, vascular damage to the placenta can lead to fetal death and abortion. The virus establishes persistent infection in the reproductive tract of some stallions, where testosterone-dependent mechanisms allow continued virus shedding in semen despite the presence of antibodies.

Early warning signs of Equine Viral Arteritis may be subtle and nonspecific, requiring vigilant observation particularly in at-risk populations during breeding season or following potential exposure. Initial indicators often include mild fever, decreased appetite, or subtle lethargy that may be attributed to other causes. Some horses develop slight nasal discharge or increased lacrimation before more characteristic signs appear. Mares bred recently may show early signs of reproductive tract inflammation. Because horses naturally hide signs of illness, early detection requires attentive daily monitoring and familiarity with each horse's normal behavior and appearance.

Common symptoms of EVA reflect the virus's effects on the vascular system and include fever ranging from 102 to 106 degrees Fahrenheit, often persisting for two to nine days. Limb edema is characteristic, affecting one or more legs with swelling that may range from mild stocking up to severe filling that extends up the limbs. Periorbital edema causes swelling around the eyes, giving affected horses a characteristic puffy appearance. Conjunctivitis with redness and discharge from the eyes has led to the colloquial name "pink eye" in some regions. Nasal discharge, typically serous to mucopurulent, accompanies respiratory tract inflammation.

Behavioral changes in horses with EVA include depression, reduced appetite, and reluctance to move, particularly when edema affects the limbs and causes discomfort. Affected horses may appear stiff and uncomfortable, seeking to remain stationary rather than walking. Some horses show muscle stiffness or soreness beyond what edema alone would explain. Pregnant mares may show behavioral signs of impending abortion. Stallions may show decreased libido and changes in breeding behavior during clinical illness. General malaise and reduced interaction with handlers or herd mates commonly occurs.

Physical signs of EVA extend beyond the typical findings and may include ventral edema affecting the sheath or mammary gland region, scrotal swelling in stallions, and urticaria or hives on various parts of the body. Respiratory signs may progress to include coughing and increased respiratory effort in some cases. Oral ulcers or lesions on the mucous membranes occur occasionally. Skin lesions, including areas of hair loss or crusting, have been reported in some outbreaks. Abortion in pregnant mares occurs typically in the later stages of pregnancy and may be the first indication of EVA in a herd when other signs are subtle.

Symptom progression in EVA typically follows a course of one to two weeks from onset to resolution in uncomplicated cases. Fever is usually one of the first signs and may precede other symptoms by a day or two. Edema and respiratory signs typically develop within the first few days of fever onset. Peak clinical signs usually occur during the first week of illness, followed by gradual improvement as the immune response controls viral replication. Most horses show significant improvement by ten to fourteen days after onset, though some residual edema may persist longer. Recovery is usually complete in adult horses.

Emergency symptoms requiring immediate veterinary attention include signs of severe respiratory distress, marked depression suggesting potential secondary complications, abortion or impending abortion in pregnant mares, and illness in young foals who may develop severe, potentially fatal disease. Stallions showing severe scrotal swelling may experience compromised fertility and require prompt evaluation. Any horse that fails to improve as expected or shows deterioration after initial improvement warrants reassessment. Secondary bacterial infections may complicate recovery and require specific treatment. Cases with unusually severe signs or affecting multiple animals simultaneously should prompt immediate biosecurity measures and veterinary consultation.

Physical examination of horses with suspected EVA involves comprehensive assessment of clinical signs while collecting information needed to guide testing and management. The veterinarian evaluates fever, respiratory rate and effort, and cardiovascular parameters. Examination of the eyes assesses for conjunctivitis and periorbital edema. Limb palpation characterizes the location and severity of edema. Examination of the sheath, udder, or scrotum detects edema in these regions. Auscultation of the lungs may reveal abnormal sounds indicating respiratory involvement. Evaluation of pregnant mares includes assessment of fetal viability when possible. The clinical picture guides initial management while diagnostic testing confirms the diagnosis.

Diagnostic tests for EVA include serological testing to detect antibodies and virological testing to detect the virus itself. Serum neutralization testing is the gold standard for antibody detection and is used for regulatory purposes and surveillance. A single positive antibody test indicates previous exposure or vaccination but cannot distinguish between the two or confirm active infection. Demonstration of seroconversion through rising antibody titers between acute and convalescent samples provides evidence of recent infection. Virus isolation from nasopharyngeal swabs, blood, semen, or tissue samples provides definitive diagnosis of active infection. PCR testing offers rapid, sensitive detection of viral genetic material.

Advanced diagnostics may be employed in specific situations to characterize virus strains or assess the implications of infection. Genetic sequencing of virus isolates can help trace the source of outbreaks and determine relationships between strains. Semen evaluation in stallions includes testing for virus shedding to determine carrier status. Necropsy with histopathology provides definitive diagnosis in fatal cases and characterizes the extent of vascular lesions. Fetal and placental examination following abortion helps confirm EVA as the cause. Test-breeding of antibody-positive stallions to seronegative mares with subsequent mare testing is the definitive method to determine carrier status.

Differential diagnosis for EVA includes other conditions causing similar combinations of fever, edema, and respiratory signs. Equine influenza causes respiratory disease but typically without the characteristic edema of EVA. Equine herpesvirus infections cause respiratory disease and abortion but have different edema patterns. Purpura hemorrhagica following strangles infection causes severe edema but typically shows petechia and has distinct history. Poisoning with certain plants or toxins may cause edema patterns. African horse sickness, in regions where it occurs, must be considered. Bacterial infections including septicemia can cause fever and edema. Allergic reactions may produce urticaria and facial swelling. Careful evaluation of history, clinical signs, and appropriate testing distinguishes EVA from these other conditions.

Emergency treatment for horses with severe EVA focuses on supportive care and management of complications while the immune system clears the viral infection. There is no specific antiviral medication for EVA, so treatment is symptomatic. Horses with high fever benefit from antipyretic and anti-inflammatory medication such as non-steroidal anti-inflammatory drugs. Those with severe respiratory involvement may require oxygen supplementation or other respiratory support in rare cases. Pregnant mares showing signs of impending abortion may benefit from hormone therapy and supportive care, though success in preventing abortion is limited. Foals with EVA may require intensive supportive care including fluids and nutritional support.

Medical management of EVA centers on anti-inflammatory therapy and supportive care to reduce discomfort and support recovery. Non-steroidal anti-inflammatory drugs such as phenylbutazone or flunixin meglumine reduce fever, alleviate discomfort from edema and muscle soreness, and generally improve patient comfort. Diuretics are sometimes used to help resolve severe edema, though their benefit is debated. Cold therapy and bandaging may help manage limb edema. Adequate nutrition and hydration support the immune response and recovery. Rest and reduced stress allow the horse to devote energy to fighting infection.

While surgical treatment is not applicable to EVA, management of carrier stallions involves important reproductive decisions. Stallions that become persistent shedders following infection continue to carry the virus in the reproductive tract and shed it in semen indefinitely. Options for managing carrier stallions include using them only to breed previously vaccinated or seropositive mares, maintaining them in isolation from naive horses, or retiring them from breeding. Castration of carrier stallions eliminates the carrier state as the testosterone-dependent virus persistence requires intact reproductive tract. The decision regarding carrier stallion management depends on the animal's value, intended use, and available facilities for appropriate management.

Supportive care during EVA infection includes attention to general husbandry needs while minimizing stress that could prolong recovery. Affected horses should be kept comfortable with appropriate bedding, good ventilation without drafts, and access to fresh water and palatable feed. Horses with severe limb edema may benefit from controlled hand-walking once fever resolves to promote lymphatic drainage. Secondary bacterial infections should be treated appropriately with antimicrobials when indicated. Careful monitoring for complications ensures prompt intervention if needed. Biosecurity measures during treatment protect other horses on the premises.

Rehabilitation following EVA is typically straightforward for horses with uncomplicated disease. Once fever resolves and clinical signs improve, horses can gradually return to normal activity. The timeline for return to work depends on severity of illness and the horse's intended use. Most horses can resume light work within two to three weeks of recovery and return to full work within a month or two. Mares that aborted may require additional recovery time before breeding again. Stallions should be tested to determine carrier status before resuming breeding activities. Competition horses must meet any applicable testing requirements before participating.

Treatment decisions for EVA-affected horses generally favor conservative management given the typically self-limiting nature of the disease. The primary treatment goals are maintaining comfort and preventing complications rather than attempting to accelerate viral clearance. Decisions regarding breeding animals are more complex and must consider carrier status, regulatory requirements, and breeding program goals. Pregnant mare management during outbreaks involves weighing the risks and benefits of various intervention strategies. Consultation with veterinarians experienced in EVA management and with reproductive specialists as appropriate guides optimal treatment decisions.

Recovery timeline for horses with acute EVA typically spans two to three weeks from onset of clinical signs to complete resolution. Fever usually resolves within the first week as the immune response begins to control viral replication. Edema gradually diminishes over one to two weeks, though some residual filling may persist longer in some cases. Respiratory signs improve concurrently with other symptoms. Most horses appear clinically normal by three to four weeks after onset, though they may continue shedding virus for several additional weeks. Full return to previous condition and work capability is expected for uncomplicated cases.

Post-treatment care and monitoring following EVA focus on confirming complete recovery and identifying any complications. Horses should be observed for resolution of all clinical signs before return to work or breeding activities. Repeated serological testing documents antibody response to infection. Stallions require specific testing to determine whether they have become carriers, typically performed no sooner than 28 days after infection and repeated if initial results are negative but clinical suspicion persists. Mares that aborted should be evaluated for reproductive tract health before rebreeding. Documentation of infection and recovery is important for regulatory and breeding management purposes.

Prognosis factors influencing recovery from EVA include age of the affected horse, severity of clinical signs, and whether complications develop. Young foals may experience severe, potentially fatal disease and have more guarded prognosis than adult horses. Horses with mild clinical signs recover quickly and completely. Those with severe respiratory involvement or significant complications may have prolonged recovery. Abortion, while devastating for breeding programs, does not typically affect the mare's long-term reproductive capacity. The primary factor affecting long-term outcome for stallions is whether they become persistent carriers.

Long-term outlook for EVA survivors is generally excellent, with most horses returning to full health and function. Recovery from acute infection confers immunity that protects against clinical disease upon re-exposure, though immunity does not prevent reinfection in all cases. Mares that aborted can typically conceive and carry subsequent pregnancies normally. Performance horses can return to competition once recovered. The main long-term concern involves carrier stallions, who remain infectious and must be managed accordingly for the remainder of their breeding careers. Non-carrier stallions have no lasting effects from EVA infection.

Management practices for EVA prevention focus on controlling exposure through testing, isolation, and careful breeding management. Testing stallions for EVA before breeding season identifies carriers that require special management. Newly arrived horses should be quarantined and tested before contact with resident populations. Mares should be bred only to stallions of known EVA status, with appropriate precautions when using carrier stallions. Breeding facilities should implement biosecurity protocols that prevent respiratory transmission during outbreaks. Isolation of clinically ill horses during acute infection limits respiratory spread to susceptible contacts.

Vaccination plays a central role in EVA prevention strategy, though it must be applied thoughtfully given regulatory and testing implications. A modified live vaccine is available and effectively prevents clinical disease and abortion in mares. However, vaccinated horses seroconvert and become indistinguishable from naturally infected horses on standard serological tests. Therefore, vaccination of breeding animals should be performed only with documented pre-vaccination seronegative status and maintained records. Colts intended for breeding should be vaccinated before puberty to prevent the carrier state if exposed, but only after baseline seronegative testing. Annual revaccination maintains protection.

Breeding management for EVA prevention includes specific protocols for using carrier stallions while protecting susceptible mares. Carrier stallions should be bred only to mares that are either vaccinated at least three weeks prior or naturally seropositive from previous exposure. Naive mares bred to carrier stallions will become infected and may develop clinical signs, including abortion if pregnant. Artificial insemination with semen from carrier stallions carries the same infection risk as natural breeding. Some breeding programs choose to avoid carrier stallions entirely, while others maintain strict protocols for their appropriate use. Documentation of mare EVA status is essential for safe breeding management.

Environmental factors influencing EVA transmission can be managed through appropriate facility design and management. Adequate spacing between horses reduces aerosol transmission of respiratory secretions. Good ventilation in barns dilutes viral concentration in the air. Prompt removal and proper disposal of aborted fetuses and placental material eliminates a significant virus source. Disinfection of breeding equipment and artificial insemination supplies prevents fomite transmission. While the virus is relatively fragile in the environment, minimizing environmental contamination supports overall prevention efforts.

Regulatory testing requirements form an important component of EVA control in many regions and for international horse movement. Many countries require EVA testing of breeding stallions and may restrict importation of seropositive animals. Testing requirements for international competition may apply. Breeding registries may have specific EVA policies affecting registration of foals or approval of breeding stallions. Understanding and complying with applicable regulations is essential for breeding operations. Maintaining accurate records of vaccination status, test results, and breeding activities provides documentation needed to satisfy regulatory requirements and manage breeding programs effectively.

Daily management adjustments for horses diagnosed with EVA include isolation protocols, supportive care routines, and enhanced monitoring. Affected horses should be isolated from susceptible animals to prevent respiratory transmission, with separate air space when possible. Handlers should use dedicated protective equipment and follow biosecurity practices to prevent mechanical transmission. Daily monitoring includes temperature measurement, assessment of clinical signs, and documentation of progress. Medication administration follows the prescribed schedule. Attention to nutrition and hydration supports recovery. Management of breeding animals includes suspension of breeding activities until appropriate testing confirms safety.

Housing and turnout considerations during EVA infection prioritize isolation while maintaining horse welfare. Isolation facilities should be located away from susceptible horses, ideally in a separate building with independent ventilation. Solid walls rather than open partitions between stalls reduce aerosol transmission. Affected horses should not share paddocks or pastures with uninfected animals. If isolation facilities are limited, the highest-risk susceptible animals, particularly pregnant mares and naive breeding stallions, should be given priority protection. Return to normal housing can occur after clinical recovery and when viral shedding has ceased.

Exercise modifications during EVA recovery depend on clinical status and stage of illness. During acute illness with fever, rest is essential and horses should not be exercised. As horses recover and fever resolves, controlled hand-walking may begin, which can help reduce edema in the limbs. Gradual return to normal exercise follows clinical recovery. Competition horses must meet any applicable testing or waiting period requirements before returning to sanctioned events. Breeding stallions require confirmation of non-carrier status before returning to breeding activities, which may extend the period before full return to normal management.

Monitoring and ongoing care after EVA infection includes both health monitoring and testing to determine long-term implications. Clinical observation ensures complete resolution of all signs before discontinuing supportive care. Serological testing documents the immune response to infection. Carrier testing for stallions requires specific protocols and timing. Documentation of the infection episode, test results, and recovery supports future health management and regulatory compliance. On farms that experienced EVA outbreaks, enhanced surveillance during subsequent breeding seasons helps detect any recurrence.

Quality of life considerations for EVA-affected horses are generally favorable given the typically complete recovery from acute infection. Most horses experience temporary discomfort during clinical illness that resolves fully with supportive care. Long-term quality of life is not typically affected for horses that recover from uncomplicated EVA. Carrier stallions can continue to breed when managed appropriately, though their use may be restricted to certain mares. The psychological impact of isolation during illness is temporary, and horses return to normal social interactions after recovery. Overall, EVA has minimal lasting impact on quality of life for most affected horses.

While no breed has inherent genetic susceptibility to EVA, certain breeds have higher seroprevalence due to historical patterns of virus circulation within their populations. Standardbreds have notably high seroprevalence rates in many countries, with some populations showing exposure rates above 80 percent. This reflects endemic circulation of the virus within the breed population over many decades. Warmblood breeds in some regions have moderate seroprevalence. Thoroughbreds historically had low seroprevalence, making them vulnerable when outbreaks occurred, though increased awareness and control measures have improved surveillance. Draft breeds, Arabians, and other populations have variable exposure rates depending on regional and management factors.

Use and discipline considerations influence EVA exposure risk through management practices rather than inherent susceptibility. Breeding populations face highest risk due to venereal transmission from carrier stallions. Operations that utilize artificial insemination with transported semen may introduce virus from distant sources. Show and competition horses that commingle at events have exposure opportunities through respiratory transmission. Horses maintained in closed populations with limited outside contact have reduced exposure risk. Racing industries with strict EVA controls have successfully maintained low seroprevalence through testing and management protocols. Recreational horses with limited breeding exposure and event attendance typically have low EVA risk.

Genetic testing for EVA susceptibility is not applicable as the disease is infectious rather than hereditary. However, testing stallions for carrier status is essential for breeding management. Stallions should be tested prior to first breeding and monitored if exposed to EVA subsequently. The choice to use carrier stallions in breeding programs depends on the ability to manage mare vaccination and the goals of the breeding program. Some breed registries and export markets restrict the use of carrier stallions or require specific documentation. Breeding decisions should consider both the immediate management requirements and the long-term implications for foal marketing and international movement potential.

Commonly co-occurring conditions with EVA may include secondary bacterial infections that develop when viral damage to respiratory tract or other tissues allows opportunistic bacterial invasion. Bacterial pneumonia can complicate primary EVA respiratory involvement, requiring antimicrobial treatment. Secondary bacterial infections of the reproductive tract may occur in stallions or mares. Horses stressed by EVA infection may experience exacerbation of other health conditions or be more susceptible to other infections. Parasitism, poor nutrition, or other concurrent health issues may worsen prognosis. Foals from mares that aborted due to EVA may have been affected by concurrent infections or other problems.

Conditions with similar symptoms to EVA create differential diagnostic challenges. Equine influenza causes respiratory disease and fever but lacks the characteristic edema pattern. Equine herpesvirus infections, particularly EHV-1 and EHV-4, cause respiratory disease and can cause abortion but have different clinical presentations. Strangles and other bacterial respiratory infections may present with fever and nasal discharge. Purpura hemorrhagica following streptococcal infection causes dramatic edema but typically includes petechial hemorrhages. African horse sickness, where it occurs, causes severe edema and respiratory signs. Various toxic exposures can cause edema. Allergic reactions may cause facial swelling and urticaria resembling some EVA presentations.

Potential complications of EVA include sequelae of severe acute infection and long-term implications of carrier status. Secondary bacterial infections may prolong recovery and require additional treatment. Rarely, severe cases may result in death, particularly in young foals. Stallions that become carriers face lifelong management requirements and may have restricted breeding opportunities. Mares that abort may experience complications affecting subsequent fertility, though this is uncommon. Economic losses from outbreak situations extend beyond direct animal health costs to include breeding disruptions, market impacts, and regulatory compliance expenses. Farms that experience EVA outbreaks may face lasting reputation effects in the breeding industry.